Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study

Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT)

“…Oral DAAs have radically changed the management of patients with chronic HCV infection, and a sustained viral response (SVR) higher than 90% is now obtained in patients with compensated cirrhosis. In patients with decompensated cirrhosis, SVR rates are very high but lower than in compensated cirrhosis . Interestingly, in these patients, viral clearance can result in significant laboratory and clinical improvement .…”

“…In patients with decompensated cirrhosis, SVR rates are very high but lower than in compensated cirrhosis. 7,8,[10][11][12][13][14][15][16]18 Time period…”

“…The long‐term impact of HCV treatment in patients with HCV cirrhosis and its effect on LT candidacy, however, remain to be seen . Indeed, by treating waitlisted patients and eradicating HCV, reduction in MELD score together with clinical improvement may result in delisting from the waiting list (WL) .…”

“…5 The long-term impact of HCV treatment in patients with HCV cirrhosis and its effect on LT candidacy, however, remain to be seen. 13 Indeed, by treating waitlisted patients and eradicating HCV, reduction in MELD score together with clinical improvement may result in delisting from the waiting list (WL). 14,15 In some cases though, the improvement of the MELD score may not reach the point of delisting and/or may not be followed by relevant clinical improvement, leaving the patient with a lower MELD score that reduces the probability of receiving a LT under the current MELD allocation system (the so-called MELD purgatory or limbo).…”

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

“…57 Somewhat similar results have been shown by other studies. 103,104 However, it must be understood that factors that determine improvement after DAA treatment in decompensated cirrhosis have not been fully elucidated. Analysis of data from European Liver and Intestine Association Study 63 suggests that patient with MELD scores less than 16 had high chance (25/51; 49.%) of improving and being delisted from liver transplant list.…”